Cross-elbow stent placement for refractory arteriovenous fistula stenosis and chronic total occlusion in hemodialysis patients: a single-center retrospective cohort of 42 cases
Oct 2026· Renal Failure· Vol 48· 0 citations· 19 references
Medicine
TL;DR
Cross-elbow stenting was technically feasible and provided favorable short- to mid-term patency without device-related complications, supporting its use as a salvage option for selected refractory AVF lesions and CTOs.
Abstract
Abstract Cross-elbow stent placement in hemodialysis arteriovenous fistulas (AVFs) has been avoided due to risks of fracture, kinking, deformation, migration, and infection. However, elbow lesions may be refractory to angioplasty and progress to chronic total occlusion (CTO). We evaluated the safety, feasibility, and patency of cross-elbow stenting for AVF salvage. Consecutive adult hemodialysis patients who received cross-elbow stents for clinically significant AVF stenosis or CTO (September 2021 – March 2026) at a single center were retrospectively analyzed. Primary outcomes were target lesion primary patency (TLPP), access circuit primary patency (ACPP), access circuit secondary patency, and access circuit assisted primary patency, estimated by Kaplan–Meier. Technical and clinical success and complications were recorded. Forty-two patients were included; 45.2% had CTO and 57.1% had prior PTA. Eluvia-based stents were used in 83.3%. Technical and clinical success were both 100%. Mean access flow increased from 407 ± 267 to 839 ± 188 mL/min. TLPP at 3, 6, 12, and 24 months was 90.1%, 84.4%, 76.9%, and 76.9%, respectively. No stent fracture, migration, kinking, or infection occurred. Cross-elbow stenting was technically feasible and provided favorable short- to mid-term patency without device-related complications, supporting its use as a salvage option for selected refractory AVF lesions and CTOs.
Background: The global burden of end-stage renal disease (ESRD) continues to increase, leading to a growing demand for durable hemodialysis vascular access. Percutaneous transluminal angioplasty (PTA) remains the standard treatment for stenotic lesions within the dialysis access circuit; however, the comparative effect...
Elsayed Younes, Najib A. Alaskary, Ahmed O. Korany et al.· International Journal of Dru...· 0 citations
Stent graft placement provided durable patency at the target venous anastomosis, however, the primary site of access failure shifted to the intra-arteriovenous graft segment, driving high reintervention rates, and these findings highlight the need for therapeutic strategies targeting the graft body to reduce the overal...
K. Suemitsu, Masaaki Murakami, Masahito Miyamoto· Journal of Endovascular Ther...· 0 citations
Objectives: This study aimed to compare the safety and efficacy of rotational atherectomy combined with drug-coated balloon angioplasty (RA+DCB) versus DCB alone in patients with superficial femoral artery chronic total occlusions (SFA CTOs) and to evaluate the influence of lesion complexity and vascular access site (f...
I. Oz, Emre Karacay, Betül Ozaslan et al.· Journal of Clinical Imaging...· 0 citations
Background/aim: Vascular access failure remains a major cause of morbidity in patients undergoing hemodialysis. This study aimed to evaluate the types of endovascular interventions performed for hemodialysis-related vascular complications, as well as their technical success and patency outcomes, at a single center.
Mat...
A. C. Karabörk Kılıç, B. Akhan, N. Ibrahimkhanli et al.· Turkish Journal of Medical S...· 0 citations
Using BMS is a safe and effective method to treat iliac vein stenosis with ipsilateral AVG according to a single-center retrospective analysis of a small case series in hemodialysis patients with lower extremity arteriovenous grafts.
Ya-Xue Shi, Xue-Dong Bao, Xin-Yi Fu et al.· Renal Failure· 0 citations
Summary: Background: Inferior vena cava (IVC) obstruction may cause acute descending thrombosis, post-thrombotic syndrome, or chronic venous insufficiency. Endovascular IVC stent reconstruction may improve clinical outcomes but the risk of patency loss is considerable. Stent design might impact the patency rates, but d...
G. Forgo, S. Cardi, S. Wolf et al.· VASA. Zeitschrift fur Gefass...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.